News Release
Immunomet Therapeutics Inc. announces publication of “First-in-human study of IM156, a novel biguanide oxidative phosphorylation (OXPHOS) inhibitor, in patients with advanced solid tumors”.
July 14, 2022 – Houston, Texas
Immunomet Therapeutics Inc. announced the publication of its clinical study demonstrating that IM156 was well tolerated and a recommended Phase 2 Dose for future clinical studies was established. The paper, entitled “First-in-human study of IM156, a novel potent biguanide oxidative phosphorylation (OXPHOS) inhibitor, in patients with advanced solid tumors“ was published in the journal Investigational New Drugs in collaboration with an international team of researchers at leading institutions, including:
- MD Anderson Cancer Center , The University of Texas, Houston, TX;
- Yonsei Cancer Center, Yonsei University College of Medicine, Yonsei University Health System, Seoul
- Song-Dang Institute for Cancer Research, Yonsei University College of Medicine, Seoul
- Hematology and Oncology, Department of Internal Medicine, CHA Bundang Medical Center, Seongnam
- Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
- Institute of Drug Research and Development, College of Pharmacy, Chungnam National University, Daejeon
- Department of Pharmacology, College of Medicine, The Catholic University of Korea, Seoul
“Having these study results published in the peer reviewed journal, Investigational New Drugs, provides important external validation of their impact” said Sungwuk Kim, Executive Chairman of Immunomet Therapeutics. “Importantly, this study, in combination with recently completed Phase 1 studies in healthy subjects, as well existing and emerging preclinical data that strongly implicate a critical role for OXPHOS in numerous tumor types, positions ImmunoMet to advance IM156 to clinical evaluation in carefully selected patient populations that are expected to respond to inhibition of OXPHOS”.
About IM156 IM156 is a Protein Complex 1 (PC1) inhibitor that targets the oxidative phosphorylation (OXPHOS) pathway, decreasing the supply of energy and anabolic precursors that are required to drive tumor growth and fibrotic disease. IM156, ImmunoMet’s lead drug candidate, is solely owned by ImmunoMet and is currently in development for the treatment of selected cancers and fibrosis.
About ImmunoMet Therapeutics ImmunoMet is a clinical stage biotechnology company targeting metabolism for the treatment of cancer and fibrotic diseases. ImmunoMet’s lead molecule, IM156, is a PC1 inhibitor and is the first potent PC1 inhibitor to complete Phase 1 with good tolerability. In addition to IM156, ImmunoMet owns a large library of biguanides with the potential for development, internally or with partners, across multiple indications. The company was founded in 2015 and is headquartered in JLABS @ TMC in Houston. For more information about the company, please visit www.immunomet.com.
Forward-Looking Statements This press release contains “forward-looking statements” concerning the development of ImmunoMet products, the potential benefits and attributes of those products, and the company’s expectations regarding its prospects. Forward-looking statements are subject to risks, assumptions and uncertainties that could cause actual future events or results to differ materially from such statements. These statements are made as of the date of this press release. Actual results may vary. ImmunoMet undertakes no obligation to update any forward-looking statements for any reason.
Company Contacts Sungwuk Kim Executive Chairman swkim@immunomet.com
Michael Bell Chief Financial Officer mbell@immunomet.com